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Abstract
Atherosclerosis and disorders associated with cardiovascular system remain the major
problem of modern medicine and the leading cause of mortality in developed countries.
According to the current knowledge, atherosclerosis development can begin early in
life. Clinically silent early‐stage lesions can be detected in a large population of young
adults.  Despite  substantial  progress  in  the  recent  years,  therapy of  atherosclerosis
mostly remains limited to plasma lipid profile correction. Moreover,  no therapy is
currently available for the treatment of asymptomatic early stages of the disease. The
existing synthetic drugs could not be used for this purpose, because of the unfavourable
risk/benefit ratio and high cost of treatment, which has to be long‐lasting. In this regard,
medications  based  on  natural  agents  with  anti‐atherosclerotic  activity  may  offer
interesting possibilities. Current research should focus on detection and evaluation of
such agents. One of the important tools for anti‐atherosclerotic drug evaluation is a cell‐
based model,  which allows measurement of intracellular lipid accumulation.  Anti‐
atherosclerotic activity of various substances can therefore be evaluated by the decrease
of intracellular lipid storage. In this chapter, we will  discuss the development and
application of cellular models based on primary culture of human arterial wall cells that
are suitable for detection and measurement of anti‐atherosclerotic activity of various
substances.  Using  these  models,  several  natural  agents  have  been  successfully
evaluated,  which  led  to  the  development  of  pharmaceutical  products  with  anti‐
atherosclerotic activity based on botanicals.
Keywords: atherosclerosis, arteries, cholesterol accumulation, cellular models, anti‐
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1. Introduction
Atherosclerosis remains one of the most challenging problems of modern medicine. Epide‐
miological data on atherosclerosis and cardiovascular diseases are frequently updated and
demonstrate an increase in overall mortality, partly because of the ageing of human popula‐
tion, especially in favourable economic conditions [1]. In developed countries, cardiovascular
diseases remain the primary cause of overall morbidity and mortality [2]. Atherosclerotic
lesions develop in the walls of large arteries and cause occlusion of blood vessels as a result
of either arterial wall thickening or thrombus formation on the surface of unstable plaques.
This latter condition is especially dangerous, since it can lead to a sudden and often fatal
thromboembolia, which represents the first clinical manifestation of atherosclerosis in many
patients. By contrast, early stages of the disease usually pass unnoticed. Recent studies have
demonstrated that asymptomatic atherosclerosis is, in fact, a widespread condition among
young adults [2–5]. In this cohort of subjects, the incidence of atherosclerotic lesions reaches
100%, although no clinical manifestations can be observed [3–5].
The development of atherosclerosis is a complex process, which, despite the significant
progress made during the last decade, still remains to be fully understood. Atherosclerosis
and related cardiovascular disorders are associated with several known risk factors, including
elevated plasma cholesterol level, diabetes, tobacco smoking and others [6, 7].
Modern atherosclerosis prevention strategies are largely based on elimination or attenuation
of relevant risk factors, which slows down the atherosclerotic plaque progression in an indirect
way [8]. For instance, statins are commonly used for plasma cholesterol reduction and
attenuation of atherosclerosis progression. However, limited indications and serious side
effects make statins unsuitable for preventive therapy of atherosclerosis, which has to be long‐
term. Currently, there exists no widespread “direct” anti‐atherosclerotic therapy that could be
suitable for treatment of the early, subclinical stages of the disease. Such therapy should target
the molecular and cellular mechanisms of atherogenesis at the level of blood vessel wall and
should result in prevention of de novo lesion formation or regression of existing plaques [8–
10]. Natural agents appear to be attractive candidates for preventive anti‐atherosclerosis
therapy because of their favourable safety profile and low cost. Because of their complex
composition, biologically active substances of botanical origin and their combinations may
have a wider range of effects than synthetic drugs, targeting several atherosclerosis risk factors
simultaneously. It is therefore possible that the botanical substances can possess both direct
and indirect anti‐atherosclerotic effects, such as protective activity at the cellular level com‐
bined with cholesterol lowering and hypotensive activity. Current knowledge of cardiopro‐
tective effects of natural agents and nutraceuticals is rather limited, although they have been
actively studied by several groups during the recent years [11–17]. It is important to establish
novel anti‐atherosclerotic preventive therapies based on natural products and confirm their
effectiveness by clinical studies.
The search for potential anti‐atherosclerotic agents and evaluation of their activity requires
adequate test models. Lipid accumulation is one of the most prominent features of athero‐
sclerotic lesions. Lipid uptake and storage are performed by several cell types of the arterial
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wall. Both resident cells and inflammatory cells that are recruited to the lesion site can
participate in the process. Increased lipid content can be observed already at the earliest stages
of the plaque development. The main source of cholesterol deposit in the arterial wall is low‐
density lipoprotein (LDL), especially its modified, atherogenic forms. The risk of atheroscle‐
rosis development has been demonstrated to be associated with unfavourable plasma lipid
profile and the increased contents of atherogenic LDL types, such as small dense LDL [18]. The
ability of the blood plasma to cause lipid accumulation in the arterial wall cells is referred to
as blood serum atherogenicity [19]. Anti‐atherosclerotic effect of a substance can be evaluated
by its ability to prevent lipid accumulation in cultured arterial wall cells induced by the
exposure to atherogenic LDL. Importantly, lipid profile in cells with or without treatment can
precisely be measured to quantitatively evaluate anti‐atherosclerotic potential.
In this chapter, we will give an overview of current knowledge on atherosclerotic lesion
progression and discuss the development and application of models based on primary culture
of human arterial wall cells.
2. Atherosclerotic plaque development
According to the classic lipid theory of atherogenesis, atherosclerotic lesion development is
caused by extracellular and intracellular lipid accumulation in the intimal layer of the arterial
wall [20, 21]. It has been shown that the major source of lipid accumulation in the intimal cells
is circulating LDL, especially its atherogenic forms, such as chemically modified and aggre‐
gated LDL. Chemical modification of lipoprotein particles appears to be necessary for the
atherogenic effect, since native (non‐modified) LDL added to cultured cells could not induce
significant lipid accumulation. Atherogenic modifications of LDL in the bloodstream include
desialylation, acquisition of negative charge and increase of the particle hydrated density
(small dense LDL formation). All these modifications can be accompanied by oxidation [22–
25]. Study of the atherogenic LDL modification in the bloodstream currently remains chal‐
lenging. Different laboratory methods of LDL isolation, quantification and analysis deliver
different results, which hinders direct comparison of studies employing different methods and
protocols. For instance, analysing LDL size and density by ultracentrifugation in different
buffers will give slightly different outcome. Moreover, no consensus has been reached so far
on the classification of LDL subfractions [22]. It is likely that LDL particles undergo multiple
atherogenic modification in human plasma, but the resulting products are differently evalu‐
ated by different methods from several laboratories [26–28]. One of the earliest atherogenic
modifications demonstrated to occur in human bloodstream is desialylation. The removal of
sialic acid residues from the carbohydrate components of LDL particles is performed by trans‐
sialidase, which is active in the bloodstream. Increased level of circulating modified LDL leads
to aggregation of the particles, which is facilitated by increased surface charge. The resulting
large complexes have especially high atherogenic potential. Moreover, modified forms of LDL
can induce formation of autoantibodies triggering inflammatory response and giving rise to
circulating immune complexes. Another feature that can significantly increase atherogenic
potential of modified LDL is its ability to associate with the components of extracellular matrix
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proteins in the subendothelial space of the arterial wall, which prolongs its residence time and
facilitates lipid accumulation. Unlike native LDL, which is internalized by cells via receptor‐
mediated uptake, modified LDL complexes enter the cells through uncontrolled phagocytosis
and follow a distinct metabolic pathway [29]. This can explain the rapid accumulation of
atherogenic modified LDL in cellular cytoplasm, mostly in the form of lipid droplets. Cells
containing large amounts of lipid inclusions in the cytoplasm are called “foam cells” because
of their microscopic appearance. Such cells commonly occur in atherosclerotic lesions.
Figure 1 shows the development of atherosclerotic lesions and the main stages of the athero‐
genesis [30]. According to the current knowledge, atherosclerotic lesion initiation is dependent
on two conditions: the presence of modified atherogenic LDL in the bloodstream in sufficient
quantities and the internalization of LDL by the arterial wall cells. The latter is usually triggered
by local disturbance of endothelial function that causes increased permeability of the endo‐
thelial lining allowing modified LDL to penetrate into the intimal layer of the arterial wall.
Atherogenic modification of LDL may also occur in the intimal layer, after the particles have
crossed the endothelial barrier. Local disturbances of endothelial function frequently take place
in certain parts of the vascular system, such as branching points and bends, where laminar
blood flow is altered [31]. Sites of the arterial wall that are especially vulnerable are marked
by altered morphology of endothelial cells and presence of enlarged multinucleated cells. The
pre‐existent mosaicism of the endothelial lining may explain the focal development of
atherosclerotic lesions. However, more studies are needed to determine the mechanisms of
endothelial dysfunction leading to atherosclerosis.
Focal lipid infiltration into the arterial wall intima marks the early stages of atherosclerotic
lesion development. Apparently, several cell types of the arterial wall participate in lipid
accumulation. Cells populating the intimal layer can be either resident mesenchymal cells,
Figure 1. Scheme showing the consecutive events in the development of atherosclerotic lesions. Reproduced with per‐
mission from [30].
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such as smooth muscle cells, or inflammatory cells, such as monocytes/macrophages, that can
be recruited from the bloodstream in large numbers by a local inflammatory response. Along
with macrophages, smooth muscular cells also take part in lipid uptake and can be transformed
into foam cells. While native LDL particles are metabolized by intimal cells through a well‐
developed and controlled receptor‐mediated endocytosis, it is likely that the LDL associations
are recognized by macrophages as pathogens that have to be cleared by phagocytosis [32].
Such clearance is accompanied by secretion of signalling molecules that attract immune cells
to the developing lesion site and therefore initiation of the inflammatory process [33]. Phago‐
cytosis‐mediated lipid accumulation in atherosclerosis can therefore be regarded as a variation
of innate immune response. Enhanced phagocytosis followed by lipid accumulation and foam
cell formation contributes to lesion development. Lipid accumulation affects intercellular
contacts that are essential for proper function of intimal wall resident cells [34]. On the other
hand, lipid accumulation also triggers processes that are typical for the reparative phase of
inflammation, such as proliferation and extracellular matrix synthesis leading to the fibrosis.
In favourable conditions, these reparation processes rapidly lead to formation of areas with
increased cellularity and extracellular matrix deposition. Gradual development of such focal
lesion areas leads to a diffuse intimal thickening, which is frequently observed in adult arteries.
However, the inflammatory response can become chronic, with continuous local lipid
infiltration, increased cellularity due to the proliferation of cells in the lesion site and enhanced
fibrosis.
Figure 2. Scheme showing the delicate balance between infiltrative and reparative phases in fatty atherosclerotic lesion.
Reproduced with permission from [30].
Atherosclerotic plaques can be protected from the bloodstream by formation of a fibrous cap,
which serves as a barrier for lipoproteins and inflammatory cells. Such isolation of the local
inflammatory site has a protective role, suppressing the inflammatory response and restoring
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the tissue functions. On the other hand, formation of fibrolipid plaques predisposed to rupture
(unstable plaques) can have fatal consequences because of thrombus formation.
In fibrolipid plaques, two opposing processes are likely to take place: infiltration and repara‐
tion that exist in a state of unstable equilibrium (Figure 2). Shifting the balance towards
reparation leads to the formation of fibrous plaques, which is a favourable outcome from the
clinical point of view. Inefficient reparation and continuous lipid infiltration cause plaque
rupture with possible thrombus formation. Lipidosis plays therefore a crucial role in athero‐
sclerotic lesion development at cellular and tissue levels and represents an important target
for the development of anti‐atherosclerotic therapy.
3. Evaluation of substances’ anti‐atherosclerotic activity using cellular
models
Preventive anti‐atherosclerotic therapy should be aimed at reduction of intracellular lipid
accumulation [35]. Such reduction can be achieved by different approaches [36]. First, the
therapy may decrease the level of circulating modified LDL. Second, it can target atherogenic
modification of LDL in the bloodstream. Third, it can reduce lipid uptake and storage by the
arterial wall cells. Finally, the therapy can be aimed at depletion of the existing intracellular
lipid stores. All these approaches can be evaluated by measuring the reduction of intracellular
lipid accumulation and the decrease of the intracellular pool of cholesterol esters [9, 37, 38]. A
number of available medications can be used to decrease blood serum atherogenicity [9, 36,
38, 39], which is defined as the ability of blood serum to induce cholesterol accumulation in
cultured cells. Blood serum from patients with coronary atherosclerosis usually has high
atherogenicity [19]. Changes of blood serum atherogenicity reflect lipid accumulation in the
arterial wall and are therefore relevant for the development of preventive therapy. Such
changes can be detected using cultured cells as models of early stages of human atherogenesis
[9, 38, 40]. Cellular models can be used for evaluation of anti‐atherosclerotic potential of
different drugs and active substances, for screening of potential anti‐atherosclerotic agents and
for evaluation of potential clinical efficacy of various molecules.
4. In vitro model
In vitro model based on primary culture of human aortic wall cells was developed for screening
of potential anti‐atherosclerotic substances. Cells were isolated from the subendothelial layer
of healthy human aortic intima, the layer of the arterial wall, which is most severely affected
in atherosclerosis [41]. The process of cell isolation from autopsy material using collagenase
and elastase treatment has been described previously [9, 42–44]. The obtained cell population
has been characterized using immunocytochemistry methods and was found to be heteroge‐
neous and containing smooth muscle cells (20–50%), pericytes (30–70%) and inflammatory
cells and tissue macrophages (10%) (Table 1) [9, 43, 44].
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Smooth muscle α‐actin+ 3G5+ 2A7+ CD45+ CD68+
89.6 ± 6.7% 45.8 ± 10.9% 24.1 ± 9.9% 3.6 ± 0.4% 5.2 ± 1.3%
Table 1. Proportion of cell types in primary culture cells isolated from human aortic subendothelial intima (% of
positive cells for each marker).
Substance References
Anti‐atherosclerotic
Cyclic AMP [9, 44, 46–49]
Prostacyclin [9, 50–54]
Prostaglandin E2 [9, 52, 55]
Artificial HDL* [56]
Antioxidants [9]
Calcium antagonists [9, 51, 57–59]
Trapidil and its derivatives [60, 61]
Lipoxygenase inhibitors [55]
Lipostabil [9]
Mushroom extracts [62]
Pro‐atherogenic
Beta blockers [58, 63]
Thromboxane A2 [51, 55]
Phenothiazine [58]
Indifferent
Nitrates [58]
Cholestyramine [58]
Sulfonylureas [64]
a HDL, high‐density lipoprotein.
Table 2. Substances that have been tested in vitro cell model.
Smooth muscle cells and pericytes were positive for smooth muscle α‐actin. Pericytes had a
distinct stellate shape and were identified using antibodies to 3G5 and 2A7 that are expressed
by resting and activated pericytes, respectively. Together, smooth muscle cells and pericytes
represented the majority of cell population in the obtained primary cultures. A smaller
population consisted of the inflammatory cells that could be detected using antibodies to
leukocyte‐specific marker CD45 and macrophage marker CD68 [45]. Cellular lipid accumula‐
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tion was induced by incubation of cells with atherogenic serum obtained from patients with
confirmed atherosclerosis. The increase of cellular cholesterol content reached as high as two
folds after a 24‐h incubation with atherogenic serum.
Potential anti‐atherogenic substances were evaluated by concomitant incubation of cells with
atherogenic serum and aqueous solutions of tested substances. Anti‐atherosclerotic effect was
measured as a decrease in the levels of intracellular cholesterol in the cells with test substances
compared to the control cells (treated with atherogenic serum only). The described model
allowed evaluating a number of different drugs and substances and detecting several novel
active molecules with anti‐atherosclerotic potential. Some substances were demonstrated to
possess a pro‐atherogenic effect, enhancing intracellular cholesterol accumulation induced by
atherogenic serum (Table 2).
5. Ex vivo model
Ex vivo model is based on primary culture of cells from unaffected human aortic intima that
are incubated with blood serum from patients treated with the substance of interest. Therefore,
potential anti‐atherogenic properties of substances are evaluated based on their pharmacody‐
namic properties, or the influence on blood serum atherogenicity after digestion and possible
metabolic modifications in patient's body. Blood samples are drawn before and after admin‐
istration of single doses of tested substances, and serum obtained from the samples is added
to cultured primary cells. Ex vivo model can be used for testing drugs with known safety
profiles, as well as various natural products.
Several studies have demonstrated successful application of this model for evaluation of anti‐
atherogenic properties of botanicals. Screening studies were performed on volunteers (groups
of 4–8 men and women 45–60 years old) with high blood serum atherogenicity. One of the
tested natural products with anti‐atherosclerotic properties was encapsulated onion (Allium
cepa) bulb powder (300 mg) (Figure 3). Administration of a single dose of the product resulted
in a moderate decrease of blood serum atherogenicity by 12, 28, and 24% from the baseline
after 2, 4, and 6 h, respectively. Another tested natural product with anti‐atherosclerotic
properties was preparation of wheat seedlings (Triticum aestivum). Administration of a single
dose of 300 mg of the preparation resulted in a pronounced reduction of blood serum athero‐
genicity after 4 h (Figure 4). Moderate but prolonged anti‐atherosclerotic effect was registered
for dry beet (Beta vulgaris) juice (encapsulated preparation of 300 mg) (Figure 5). Garlic (Allium
sativum) powder possessed a strong and prolonged effect (Figure 6). Blood serum atheroge‐
nicity was completely suppressed 4 h after administration of a single dose of 300 mg of the
preparation. Several other natural products were screened for potential anti‐atherosclerotic
activity using the ex vivo model (Table 3). The highest activity after a single dose administration
was detected for garlic powder and wheat seedlings, with garlic powder providing the
strongest effect. Importantly, anti‐atherosclerotic effects of garlic have been reported by several
independent groups during the recent years [65–67].
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Figure 3. Anti‐atherosclerotic effect of onion in ex vivo model.The study involved four volunteers (three males, one fe‐
male, mean age 57 ± 5 years) whose blood serum induced 1.3–1.5‐fold increase in cholesterol content of cells cultured
from unaffected human aortic intima (the average level of serum atherogenicity was 141 ± 4%). Intracellular cholesterol
in control cultures was 38.4 ± 1.1 mg/mg cell protein. Baseline serum atherogenicity was taken as 100%. The average
values of changes of serum atherogenicity with indication of standard errors are presented. Reproduced with permis‐
sion from [30].
Figure 4. Anti‐atherosclerotic effect of wheat seedlings in ex vivo model.The study involved eight volunteers (five
males, three females, mean age 51 ± 2 years) whose blood serum induced 1.7–2.3‐fold increase in cholesterol content of
cells cultured from unaffected human aortic intima (the average level of serum atherogenicity was 199 ± 6%). Intracel‐
lular cholesterol in control cultures was 28.0 ± 1.2 mg/mg cell protein. Baseline serum atherogenicity was taken as
100%. The average values of changes of serum atherogenicity with indication of standard errors are presented. *, Sig‐
nificant decrease of serum atherogenicity, p < 0.05. Reproduced with permission from [30].
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Figure 5. Anti‐atherosclerotic effect of beet juice in ex vivo model.The study involved eight volunteers (six males, two
females, mean age 53 ± 5 years) whose blood serum induced 1.3–2.2‐fold increase in cholesterol content of cells cul‐
tured from unaffected human aortic intima (the average level of serum atherogenicity was 161 ± 8%). Intracellular cho‐
lesterol in control cultures was 37.0 ± 3.6 mg/mg cell protein. Baseline serum atherogenicity was taken as 100%. The
average values of changes of serum atherogenicity with indication of standard errors are presented. *, Significant de‐
crease of serum atherogenicity, p < 0.05. Reproduced with permission from [30].
Figure 6. Anti‐atherosclerotic effect of garlic powder in the ex vivo model.The study involved eight volunteers (six
males, two females, mean age 53 ± 5 years) whose blood serum induced 1.3–2.7‐fold increase in cholesterol content of
cells cultured from unaffected human aortic intima (the average level of serum atherogenicity was 164 ± 9%). Intracel‐
lular cholesterol in control cultures was 39.0 ± 4.2 mg/mg cell protein. Baseline serum atherogenicity was taken as
100%. The average values of changes of serum atherogenicity with indication of standard errors are presented. *, Sig‐
nificant decrease of serum atherogenicity, p < 0.05. Reproduced with permission from [30].
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Botanical and its source The mean efficiency of atherogenic reduction
(%)
Maximum effect
(%)
Spirulina platensis powder  50.7  61 
Onion (Allium cepa) bulb powder  21.4  28 
Beet (Beta vulgaris) juice powder  30.7  40 
Wheat (Triticum vulgaris) seedlings powder  70.0  100 
Licorice (Glycyrrhiza glabra) root powder  54.6  32 
Salsola collina leaf powder  10.9  28 
Garlic (Allium sativum) bulbs powder  76.6  100 
Pine (Pinus sylvestris) needles extract  52.1  62 
*The integrated effect was calculated as a mean reduction in serum atherogenicity for 6 h after a single oral dose.
Table 3. Integral estimation of anti‐atherogenic actions of natural products*.
The described ex vivo model could be used for establishing the effective dose and posology of
the potential anti‐atherosclerotic natural products. For this purpose, blood samples were
drawn before and after (2 and 4 h) administration of a single dose to patients with high blood
serum atherogenicity. Dose dependency was tested by comparison of the effect of two different
doses. Each dose was evaluated on at least six different study participants. It was demonstrated
that the anti‐atherosclerotic effect of garlic powder was present in the dose range from 50 to
300 mg with half‐maximal effect observed at a dose of 100 mg, and maximal effect—at 150 mg.
Therefore, natural products of botanical origin can be regarded as an important source of
agents with anti‐atherosclerotic activity that can be used for the development of direct anti‐
atherosclerotic therapy. Based on the obtained results, several dietary supplements were
registered and further evaluated in clinical studies presented below.
As any model, cellular models for studying atherosclerosis development have their limita‐
tions [68–71]. Limitations of the experimental models used for atherosclerosis research have
been discussed in a number of comprehensive reviews [72–77]. However, the described test
system allows performing the initial screening for anti‐atherosclerotic activity that can be
further studied and confirmed in pre‐clinical and clinical studies.
6. Clinical studies
Tests on cellular models demonstrated that garlic powder preparations possessed a pro‐
nounced anti‐atherosclerotic activity. Based on the obtained results, a garlic‐based dietary
supplement (Allicor, INAT‐Farma, Russia) was developed. The effect of the supplement on
carotid intima‐media thickness (cIMT) was evaluated in an open‐label prospective pilot study
conducted on 28 men (46–58 years old, mean age 52.0, SD = 9.0). The study participants had no
signs of coronary heart disease, no chronic diseases requiring treatment with vasoactive drugs,
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diuretics, lipid‐lowering or antidiabetic drugs and were normolipidemic or mildly hyperlipi‐
demic. Study subjects were analysed for presence of diffuse intimal thickening by ultrasound
imaging of common carotid arteries [65]. The cut‐off cIMT value of 0.7 mm in the distal segment
of at least one common carotid artery was set up to diagnose diffuse intimal thickening. The
mean cIMT value at the baseline was 0.832 ± 0.024 mm. Study participants were divided into
two groups. Subjects from Allicor group (n = 16) received 600 mg of Allicor daily, and subjects
from the control group (n = 12) received no treatment. The total duration of the study was 12 
months, with interviews and ultrasound assessment of cIMT every 3 months. No adverse
effects were observed during the follow‐up period, and the product was demonstrated to have
good tolerability. The results of cIMT assessments are presented on Figure 7.
Figure 7. The effects of garlic‐based drug Allicor on atherosclerosis determined by cIMT. Open circles, Allicor recipi‐
ents; solid circles, control subjects. Presented are mean values ±S.E.M. Reproduced from [30].
No statistically significant changes of cIMT were observed after 12 months, and the value was
not significantly different between the two groups. However, regression analysis revealed a
significant difference between the trends of cIMT dynamics (p < 0.05). In the control group, a
tendency to cIMT increase was detected, which was significantly different from that of null
hypothesis of no change (F‐test, 31.72; p = 0.011). In the Allicor‐treated group, the tendency to
cIMT decrease was revealed, which was also significantly different from that of null hypothesis
(F‐test, 28.81; p = 0.013). These results indicate that treatment with Allicor may potentially
halter the development and induce the regression of subclinical atherosclerosis. The statistical
power of this pilot study was insufficient to avoid type 2 error. Therefore, the pilot study was
followed by a larger prospective clinical study, in which a number of clinical and biochemical
parameters associated with atherogenesis were taken into account. The dynamic of serum
atherogenicity was also assessed. This double‐blind placebo‐controlled clinical study evalu‐
ated the effect of garlic powder tablets Allicor on the progression of cIMT in 211 men (40–74 
years old) with no symptoms of atherosclerosis (ClinicalTrials.gov identifier, NCT01734707).
The primary outcome was the progression of subclinical atherosclerosis evaluated by B‐mode
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ultrasonography as the increase of cIMT. By the end of the first 12‐month follow‐up period, a
decrease of cIMT by 0.028 ± 0.008 mm was observed in the Allicor group. At the same time,
moderate increase of 0.014 ± 0.009 mm was observed in the placebo group (p = 0.002). Serum
atherogenicity was decreased in the Allicor group by 45% from the baseline and remained
unaltered in the placebo group. Therefore, long‐term treatment with Allicor had a direct anti‐
atherosclerotic effect in patients with subclinical atherosclerosis associated with decreased
serum atherogenicity [78]. By the end of the 24‐month follow‐up period, the mean rate of cIMT
was decreased in the Allicor group by 0.022 ± 0.007 mm per year, which was significantly
different (p = 0.002) from the placebo group, in which there was a moderate but statistically
significant progression of 0.015 ± 0.008 mm at the overall mean baseline cIMT of 0.931 ± 0.009 
mm [37, 39]. A significant reduction of cIMT was observed in 47.3% of study subjects from the
Allicor group vs 30.1% in the placebo group (p < 0.05). Further significant increase of cIMT was
registered in 32.2% study participants in Allicor‐treated group vs 47.3% in placebo group (p 
< 0.05). Study of blood serum atherogenicity demonstrated a 1.56‐fold increase of intracellular
cholesterol accumulation in the cellular test at the baseline. Study participants from Allicor
group had an average 30% decrease of blood serum atherogenicity, while in the placebo group,
this parameter remained unaltered during the study. A significant correlation was observed
between changes of blood serum atherogenicity and intima‐media thickness of common
carotid arteries (r = 0.144, p = 0.045) (Figures 8 and 9). Therefore, it was demonstrated that
garlic‐based food supplement Allicor possessed a direct anti‐atherosclerotic effect at the
subclinical stage of the disease, which could be attributed to the decrease of blood serum
atherogenicity [37, 39].
Figure 8. The dynamics of cIMT in double‐blind placebo‐controlled study on anti‐atherosclerotic effects of garlic‐based
drug Allicor. Hatched bars, Allicor recipients; open bars, placebo recipients. Presented are mean values ±S.E.M. *, sig‐
nificant difference between groups, p < 0.05. Reproduced with permission from [30].
Another clinical study was focused on the evaluation of potential anti‐atherosclerotic activity
of herbal products with anti–inflammatory effects. Atherosclerosis is tightly associated with
the inflammatory process at all stages of the disease development [79, 80]. Substances with
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systemic anti‐inflammatory properties can therefore be regarded as potential therapeutic
agents for treatment and prevention of atherosclerosis.
Figure 9. The dynamics of serum atherogenicity in double‐blind placebo‐controlled study on anti‐atherosclerotic ef‐
fects of garlic‐based drug Allicor. Hatched bars, Allicor recipients; open bars, placebo recipients. Presented are mean
values ±S.E.M. *, significant difference between groups, p < 0.05. Reproduced with permission from [30].
Figure 10. The changes of cIMT in double‐masked placebo‐controlled study on anti‐atherosclerotic effects of Inflami‐
nat. Presented are mean values ±S.E.M. *, significant difference between groups, p < 0.05. Reproduced with permission
from [30].
Several natural compounds, such as calendula (Calendula officinalis), elder (Sambucus nigra) and
violet (Viola sp.), were demonstrated to possess not only anti‐inflammatory, but also anti‐
atherosclerotic effects [81–83]. The combination of these herbs was used for the development
of a novel dietary supplement (Inflaminat, INAT‐Farma, Russia) [84]. The effect of Inflaminat
on cIMT dynamics was evaluated in a pilot placebo‐controlled double‐blinded study per‐
formed on 67 asymptomatic men (ClinicalTrials.gov Identifier, NCT01743404) [39, 85]. The
protocol of the 12‐month study was similar to that described for Allicor food supplement.
Administration of Inflaminat induced cIMT regression in subclinical atherosclerosis, with
statistically significant difference between the baseline as the placebo group (Figure 10).
Therefore, Inflaminat was demonstrated to possess anti‐inflammatory and anti‐atherosclerotic
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effects at the cellular level and to induce regression of subclinical atherosclerotic lesions in
asymptomatic men.
Figure 11. The changes of cIMT in double‐masked placebo‐controlled study on anti‐atherosclerotic effects of Karinat.
The data are presented in the terms of means and S.D. *, significant difference between groups, p < 0.05. Reproduced
with permission from [30].
Finally, several phytoestrogen‐rich natural substances were evaluated for potential anti‐
atherosclerotic activity using the described in vitro and an ex vivo models [86–88]. The most
promising of these compounds were garlic powder, extract of grape seeds, green tea leaf and
hop cones. All these substances possessed a significant anti‐atherogenic effect. A combination
of these compounds was used for development of a novel isoflavonoid‐rich dietary supplement
(Karinat, INAT‐Farma, Russia). The resulting supplement is a source of biologically active
polyphenols, including resveratrol, genisteine and daidzeine that are claimed to produce
beneficial effects on atherosclerosis development. The efficiency of Karinat was evaluated in a
randomized double‐blind placebo‐controlled 12‐month clinical study conducted on 157
asymptomatic postmenopausal women (ClinicalTrials.gov Identifier, NCT01742000) [89, 90].
The primary endpoint was the annual rate of cIMT change. The protocol of the study was
similar to that reported above. An annual increase of mean cIMT of more than 100 μm (13%
per year) was observed in the placebo group, indicative of a high rate of cIMT progression in
postmenopausal women. Growth of atherosclerotic plaques was estimated to be 40% per year.
In the Karinat group, mean cIMT value remained unaltered, with a statistically insignificant
increase of 6 μm per year, that is <1% (Figure 11). Therefore, phytoestrogen‐rich substances
were proven to possess beneficial effects on the dynamics of subclinical atherosclerosis
progression in postmenopausal women [39, 91].
7. Conclusions
Introduction of the concept of blood serum atherogenicity allowed creating cell model suitable
for screening of substances with potential anti‐atherosclerotic activity. Such models helped
revealing several novel compounds of botanical origin that could be used for the development
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of dietary supplements for treatment of subclinical (asymptomatic) atherosclerosis. The effect
of “direct” anti‐atherosclerotic therapy can be observed at the level of the arterial wall cells by
a decrease of intracellular lipid accumulation. Therapy of patients with established athero‐
sclerosis should induce regression of the existing plaques or hinder the progression of novel
lesions. Introduction of food supplements from botanicals with anti‐atherosclerotic properties
and suitable for long‐term consumption is an important step toward the improvement of the
preventive treatment of atherosclerosis. Further studies will help revealing natural products
with anti‐atherogenic and anti‐atherosclerotic effects that can be used for the development of
novel cardiovascular drugs possessing mechanistic mode of action. Despite the unavoidable
limitations of the described models, the obtained results have demonstrated that cultured
arterial wall cells offer a suitable instrument for initial analysis of drug effects. The discovery
of anti‐atherosclerotic activity of natural products opens great opportunities for prevention
and treatment of atherosclerotic disease, reducing cardiovascular morbidity and mortality.
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